念珠菌感染与癌症风险：一项丹麦全国队列研究。

Candida infection and cancer risk: a Danish nationwide cohort study.

机构信息

Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus N, Denmark.

出版信息

Eur J Intern Med. 2013 Jul;24(5):451-5. doi: 10.1016/j.ejim.2013.02.017. Epub 2013 Mar 22.

DOI:10.1016/j.ejim.2013.02.017

PMID:23522963

Abstract

BACKGROUND

Candida species infection may be associated with increased cancer risk.

METHODS

We linked data from the nationwide medical registries and examined the incidence of various cancers in patients with a first-time hospital presentation with candida infection. We computed the cumulative incidence of cancer and standardized incidence ratios (SIRs) of cancer overall, immune-related cancers, and specific cancer types by comparing observed versus expected incidences based on age-, sex-, and anatomical site-specific incidence rates.

RESULTS

Among 21,247 candida-infected patients, we identified 1534 cancers during a combined follow-up of 187,993 years (standardized incidence ratio (SIR)=1.6 (95% confidence interval (CI): 1.5-1.7)). The 1- and 10-year risks of cancer were 2.6%, and 8.3%, respectively. In the first year after a candida diagnosis, the SIR for cancer was 3.7 (95% CI: 3.4-4.0). In the second and subsequent years of follow-up, the SIRs were 1.2 (95% CI: 1.1-1.3) for any cancer and 1.4 (95% CI 1.2-1.7) for immune-related cancers. The risk of mouth and throat cancers remained more than 3-fold increased in the second and subsequent years of follow-up.

CONCLUSIONS

Hospital presentation with candida infection is associated with increased short- and long-term cancer risk.

摘要

背景

念珠菌属物种感染可能与癌症风险增加有关。

方法

我们将全国性医疗登记数据进行关联，并检查了首次因念珠菌感染住院的患者的各种癌症的发病率。我们通过比较基于年龄、性别和解剖部位特定发病率的观察到的与预期的发病率，计算了癌症的累积发病率和癌症的标准化发病比（SIR），以及整体免疫相关癌症和特定癌症类型的 SIR。

结果

在 21247 例念珠菌感染患者中，我们在 187993 年的联合随访中发现了 1534 例癌症（标准化发病比（SIR）=1.6（95%置信区间（CI）：1.5-1.7））。癌症的 1 年和 10 年风险分别为 2.6%和 8.3%。在念珠菌诊断后的第一年，癌症的 SIR 为 3.7（95% CI：3.4-4.0）。在随访的第二年及以后，任何癌症的 SIR 为 1.2（95% CI：1.1-1.3），免疫相关癌症的 SIR 为 1.4（95% CI 1.2-1.7）。在随访的第二年及以后，口腔和咽喉癌的风险仍然增加了 3 倍以上。